Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants (EIAC) was as follows: irinotecan 400 mg/m(2)/wee...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Jaeckle, Kurt A., Ballman, Karla V., Giannini, Caterina, Schomberg, Paula J., Ames, Matthew M., Reid, Joel M., McGovern, Renee M., Safgren, Stephanie L., Galanis, Evanthia, Uhm, Joon H., Brown, Paul D., Hammack, Julie E., Arusell, Robert, Nikcevich, Daniel A., Morton, Roscoe F., Wender, Donald B., Buckner, Jan C.
格式: Artigo
語言:Inglês
出版: 2010
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2897141/
https://ncbi.nlm.nih.gov/pubmed/20063115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-0103-2
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍